Skip to content

The Impact of Electroconvulsive Therapy on Cognitive Function and Depressive Symptoms in Adolescent Patients with Depression: A Prospective Observational Study

The Impact of Electroconvulsive Therapy on Cognitive Function and Depressive Symptoms in Adolescent Patients with Depression: A Prospective Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083405
Enrollment
Unknown
Registered
2024-04-24
Start date
2024-05-01
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

Case series (Adolescent depression patients receiving electroconvulsive therapy):None

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age 12-18 years. 2. Right-handed. 3. Diagnosed with major depression disorder (MDD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5), diagnosed by at least one deputy director of psychiatry or above physician. 4. 24-item Hamilton Rating Scale for Depression (HAMD-24) score =35, indicating severe depression. 5. This depressive episode may have self injurious suicidal behavior, or the Beck Suicide Intention Inventory (BSI-CV) suggests suicidal ideation. 6. Patients who have failed first-line treatment (such as fluoxetine, sertraline monotherapy, or combination cognitive-behavioral therapy). 7. Capable of comprehending and completing the study assessments. 8. Written informed consent provided by patients and/or their legal guardians.

Exclusion criteria

Exclusion criteria: 1. Presence of severe systemic diseases, including but not limited to severe liver, kidney, respiratory, cardiovascular, endocrine diseases, hematologic disorders, or neoplastic diseases. 2. Diagnosed with schizophrenia or any other primary psychotic disorders, bipolar disorder, dementia, substance dependence, or drug abuse according to DSM-V. 3. Significant neurological diseases that can affect cognitive function (such as autoimmune encephalitis, epilepsy). 4. Undergone electroconvulsive therapy (ECT) in the six months prior to the current hospitalization. 5. Known allergies or contraindications to concomitant drugs used in ECT. 6. Receiving repetitive transcranial magnetic stimulation (rTMS) or other neuromodulation treatments. 7. Participation in another clinical trial simultaneously.

Design outcomes

Primary

MeasureTime frame
Cambridge Neuropsychological Test Automated Battery-Spatial Recognition Memory;Cambridge Neuropsychological Test Automated Battery-Spatial Working Memory;Cambridge Neuropsychological Test Automated Battery-Rapid Visual Information Processing;Cambridge Neuropsychological Test Automated Battery-Verbal Recognition Memory;

Secondary

MeasureTime frame
24-item Hamilton Rating Scale for Depression ;Self-rated Depression Scale;Beck scale for suicide ideation - Chinese vision (BSI - CV);

Countries

China

Contacts

Public ContactLuo Qinghua

Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University

202538@cqmu.edu.cn+86 189 8361 2632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026